Tribenoside
C05A - Agents for treatment of haemorrhoids for topical use
ATC C05AX05
Small molecule
Natural product
JFDA label: PROCTO-GLYVENOL Cream
Indications
Off-label
- Cardiovascular Diseases
- Hemorrhoids
Chemistry & Properties
| Formula | C29H34O6 |
|---|
| Molecular weight | 478.59 g/mol |
|---|
| IUPAC name | (3R,4R,5R)-5-[(1R)-1,2-bis(phenylmethoxy)ethyl]-2-ethoxy-4-phenylmethoxyoxolan-3-ol |
|---|
| CAS | 10310-32-4 |
|---|
| PubChem CID | 196122 |
|---|
| InChIKey | ULLNJSBQMBKOJH-VIVFLBMVSA-N |
|---|
| logP | 4.5 (XLogP 3.9) |
|---|
| Polar surface area | 66.38 Ų |
|---|
| H-bond acceptors / donors | 6 / 1 |
|---|
| Drug-likeness (QED) | 0.39 |
|---|
| Lipinski violations | 0 |
|---|
SMILES
CCOC1O[C@H]([C@@H](COCc2ccccc2)OCc2ccccc2)[C@H](OCc2ccccc2)[C@H]1OBiology & Pharmacokinetics
Pharmacokinetics predicted
| Bioavailability | 35.0% |
|---|
| Half-life | 0.867 h |
|---|
| Volume of distribution | 0.66 L/kg |
|---|
| Protein binding | 94.2% |
|---|
| BBB penetrant | Yes |
|---|
Enzyme interactions
| Enzyme | Role | Detail |
|---|
| CYP2B6 | Inhibitor |
— |
| CYP2C8 | Inhibitor |
— |
| CYP2C9 | Inhibitor |
— |
| CYP3A4 | Substrate |
— |
Transporters
BCRP (Inhibitor)BSEP (Inhibitor)MRP1 (Inhibitor)OATP1B1 (Inhibitor)OATP1B3 (Inhibitor)P-gp (Inhibitor)P-gp (Substrate)
Registered Products (2)